Redhill Biopharma Ltd
NASDAQ:RDHL
Redhill Biopharma Ltd
Research & Development
Redhill Biopharma Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Redhill Biopharma Ltd
NASDAQ:RDHL
|
Research & Development
-$2.6m
|
CAGR 3-Years
46%
|
CAGR 5-Years
25%
|
CAGR 10-Years
17%
|
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Research & Development
-$1B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
0%
|
CAGR 10-Years
4%
|
|
|
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
Research & Development
-$24.4m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
PolyPid Ltd
NASDAQ:PYPD
|
Research & Development
-$23.8m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Research & Development
-$13.5m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-8%
|
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Research & Development
-₪4.4m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-5%
|
|
Redhill Biopharma Ltd
Glance View
RedHill Biopharma Ltd. is a biopharmaceutical company focusing gastrointestinal and infectious diseases. The firm promotes three gastrointestinal drugs in the US: Movantik, Talicia and Aemcolo. Key programs in it pipeline of late-stage clinical assets include: opaganib (Yeliva) and RHB-107 for multiple indications including COVID-19, RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease and RHB-104 for Crohn's disease.
See Also
What is Redhill Biopharma Ltd's Research & Development?
Research & Development
-2.6m
USD
Based on the financial report for Jun 30, 2025, Redhill Biopharma Ltd's Research & Development amounts to -2.6m USD.
What is Redhill Biopharma Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
17%
Over the last year, the Research & Development growth was 39%. The average annual Research & Development growth rates for Redhill Biopharma Ltd have been 46% over the past three years , 25% over the past five years , and 17% over the past ten years .
